Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds - PubMed (original) (raw)
. 2014:40 Suppl 1:S97-S111.
doi: 10.3233/JAD-132477.
Affiliations
- PMID: 24603946
- DOI: 10.3233/JAD-132477
Free article
Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds
Diana L Castillo-Carranza et al. J Alzheimers Dis. 2014.
Free article
Abstract
Neurodegenerative disease is one of the greatest health crises in the world and as life expectancy rises, the number of people affected will continue to increase. The most common neurodegenerative disease, Alzheimer's disease, is a tauopathy, characterized by the presence of aggregated tau, namely in the form of neurofibrillary tangles. Historically, neurofibrillary tangles have been considered the main tau species of interest in Alzheimer's disease; however, we and others have shown that tau oligomers may be the most toxic form and the species responsible for the spread of pathology. We developed a novel anti-tau oligomer-specific mouse monoclonal antibody (TOMA) and investigated the potential of anti-tau oligomer passive immunization in preventing the toxicity of tau pathology in Htau mice. We injected pure brain-derived tau oligomers intracerebrally in 3-month-old wild-type and Htau mice and investigated the protective effects of a single 60 μg TOMA injection when compared to the same dose of non-specific IgG and found that TOMA conferred protection against the accumulation of tau oligomers and cognitive deficits for up to 1 month after treatment. Additionally, we injected pure brain-derived tau oligomers intracerebrally in 3-month-old wild-type and Htau mice and treated animals with biweekly injections of 60 μg TOMA or non-specific IgG. We found that long-term administration of TOMA was effective as a preventative therapy, inhibiting oligomeric tau and preserving memory function. These results support the critical role of oligomeric tau in disease progression and validate tau oligomers as a potential drug target.
Keywords: Alzheimer's disease; immunotherapy; propagation; seeding; tau oligomers; tauopathies.
Similar articles
- Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Castillo-Carranza DL, et al. J Neurosci. 2014 Mar 19;34(12):4260-72. doi: 10.1523/JNEUROSCI.3192-13.2014. J Neurosci. 2014. PMID: 24647946 Free PMC article. - Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.
Bittar A, Al-Lahham R, Bhatt N, Moore K, Montalbano M, Jerez C, Fung L, McAllen S, Ellsworth A, Kayed R. Bittar A, et al. J Alzheimers Dis. 2022;90(3):1103-1122. doi: 10.3233/JAD-220518. J Alzheimers Dis. 2022. PMID: 36189593 - Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A, Bertz J, Suh LS, Stevens CH, Götz J, Ittner LM. Ittner A, et al. J Neurochem. 2015 Jan;132(1):135-45. doi: 10.1111/jnc.12821. Epub 2014 Aug 1. J Neurochem. 2015. PMID: 25041093 - Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.
Gerson JE, Castillo-Carranza DL, Kayed R. Gerson JE, et al. ACS Chem Neurosci. 2014 Sep 17;5(9):752-69. doi: 10.1021/cn500143n. Epub 2014 Aug 8. ACS Chem Neurosci. 2014. PMID: 25075869 Review. - Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F, Grueninger F, Tolnay M. Clavaguera F, et al. Neuropharmacology. 2014 Jan;76 Pt A:9-15. doi: 10.1016/j.neuropharm.2013.08.037. Epub 2013 Sep 17. Neuropharmacology. 2014. PMID: 24050961 Review.
Cited by
- Rodent models for Alzheimer's disease drug discovery.
Puzzo D, Gulisano W, Palmeri A, Arancio O. Puzzo D, et al. Expert Opin Drug Discov. 2015 Jul;10(7):703-11. doi: 10.1517/17460441.2015.1041913. Epub 2015 Apr 30. Expert Opin Drug Discov. 2015. PMID: 25927677 Free PMC article. Review. - Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3.
Ganguly P, Do TD, Larini L, LaPointe NE, Sercel AJ, Shade MF, Feinstein SC, Bowers MT, Shea JE. Ganguly P, et al. J Phys Chem B. 2015 Apr 2;119(13):4582-93. doi: 10.1021/acs.jpcb.5b00175. Epub 2015 Mar 24. J Phys Chem B. 2015. PMID: 25775228 Free PMC article. - Unraveling the Structure and Dynamics of Ac-PHF6-NH2 Tau Segment Oligomers.
Stroganova I, Toprakcioglu Z, Willenberg H, Knowles TPJ, Rijs AM. Stroganova I, et al. ACS Chem Neurosci. 2024 Sep 18;15(18):3391-3400. doi: 10.1021/acschemneuro.4c00404. Epub 2024 Aug 30. ACS Chem Neurosci. 2024. PMID: 39215387 Free PMC article. - Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.
Congdon EE, Jiang Y, Sigurdsson EM. Congdon EE, et al. Semin Cell Dev Biol. 2022 Jun;126:125-137. doi: 10.1016/j.semcdb.2021.12.002. Epub 2021 Dec 9. Semin Cell Dev Biol. 2022. PMID: 34896021 Free PMC article. Review. - Thiol-mediated and catecholamine-enhanced multimerization of a cerebrovascular disease enriched fragment of NOTCH3.
Young KZ, Cartee NMP, Ivanova MI, Wang MM. Young KZ, et al. Exp Neurol. 2020 Jun;328:113261. doi: 10.1016/j.expneurol.2020.113261. Epub 2020 Feb 28. Exp Neurol. 2020. PMID: 32119934 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials